Table 4 Recurrence risk by Cox regression analysis of non-pCR carcinoma according to Neo-Bioscore and Clustered Neo-Bioscore of low and low-intermediate risks
Characteristics | Neo-Bioscore | Low risk Clustered Neo-Bioscore | Low-intermediate Clustered Neo-Bioscore |
|---|---|---|---|
HRa (CI95%) | HR (CI95%) | HR (CI95%) | |
Menopausal status | |||
Premenopausal | Reference | Reference | Reference |
Postmenopausal | 0.75 (0.45–1.27) | 0.73 (0.19–2.77) | 0.91 (0.41–2.03) |
Histological grade | |||
I/II | Reference | Reference | Reference |
III | 1.33 (0.77–2.30) | 2.05 (0.32–13.27) | 0.77 (0.34–1.74) |
Ki-67 | |||
0–20% | Reference | Reference | Reference |
20–50% | 2.29 (0.68–7.73) | 0.76 (0.12–4.79) | 2.39 (0.29–19.89) |
≥ 50% | 3.39 (0.99–11.58) | 4.81 (0.41–56.41) | 3.37 (0.41–27.57) |
Estrogen receptor | |||
Allred 7–8 (≥70%) | Reference | Reference | Reference |
Allred 2–6 (< 70%) | 1.54 (0.49–4.88) | 2.17 (0.23–20.02) | 0.53 (0.15–1.82) |
Negative | 1.35 (0.44–4.15) | 1.33 (0.11–16.67) | 1.39 (0.16–12.50) |
HER2 | |||
Negative | Reference | Reference | Reference |
Positive | 0.58 (0.15–2.28) | 1.45 (0.34–6.17) | 0.83 (0.20–3.50) |
Tumor subtype | |||
A | Reference | Reference | Reference |
B | 0.50 (0.12–2.12) | 0.53 (0.09–3.20) | 1.10 (0.49–2.50) |
HER2 | 0.58 (0.15–2.28) | 1.45 (0.34–6.17) | 0.83 (0.20–3.50) |
TN | 1.90 (0.49–7.30) | 8.92 (0.94–84.93) | 3.60 (1.19–10.92) |
Clinical stage | |||
I/II | Reference | Reference | Reference |
III | 1.81 (0.88–3.75) | 2.70 (0.60–12.21) | 1.00 (0.38–2.66) |
Pathological stage | |||
I | Reference | Reference | Reference |
II | 8.12 (2.40–27.53) | 4.17 (0.47–37.33) | 5.35 (1.19–24.01) |
III | 16.24 (4.71–55.95) | 13.00 (1.60–106.10) | 6.56 (1.29–33.32) |